Intensity-modulated radiation therapy should be the preferred choice when treating patients with locally advanced non-small cell lung cancer, as it reduces radiation exposure to the heart and lungs, according to researchers at MD Anderson Cancer Center.
Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute said results of a phase II, multi-center clinical trial revealed that a new type of cell therapy is a promising potential treatment option for patients with stage 4 lung cancer who were previously treated but later developed resistance to other therapies.
